Evidence map›Paper›PMID 37897809›Full record

SynthesisAge and ageing2023

Antiplatelet therapy and incident cognitive impairment or dementia-a systematic review and meta-analysis of randomised clinical trials.

Kevin Kitt, Robert Murphy, Aoibhin Clarke, Catriona Reddin, John Ferguson, Jackie Bosch, William Whiteley, Michelle Canavan, Conor Judge, Martin O'Donnell

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Age and ageing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Kevin KittHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
Robert MurphyHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
Aoibhin ClarkeHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
Catriona ReddinHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
John FergusonHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
Jackie BoschPopulation Health Research Institute, Hamilton, McMaster University, Ontario, Canda.
William WhiteleyCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Michelle CanavanHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
Conor JudgeHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
Martin O'DonnellHRB-Clinical Research Facility, University of Galway, Galway, Ireland.
McMaster University · CAUniversity of Edinburgh · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectiveThe benefit of antiplatelet therapy in preventing cognitive impairment or dementia is uncertain. We investigated the association between antiplatelet therapy and incident cognitive impairment or dementia in randomised clinical trials.

methodsWe searched PubMed, EMBASE and CENTRAL for randomised clinical trials published from database inception through 1 February 2023. Trials that evaluated the association of antiplatelet therapy with incident cognitive impairment or dementia were included. For single-agent antiplatelet, the control group was placebo. For dual agent antiplatelet therapy, the control group was single-agent monotherapy. A random-effects meta-analysis model was used to report pooled treatment effects and 95% confidence intervals (CIs). The primary outcome was incident cognitive impairment or dementia. Secondary outcomes included change in cognitive test scores.

resultsA total of 11 randomised clinical trials were included (109,860 participants). All reported the incidence of cognitive impairment or dementia on follow-up. The mean (SD) age of trial participants was 66.2 (7.9) years. Antiplatelet therapy was not significantly associated with a reduced risk of cognitive impairment or dementia (11 trials; 109,860 participants) (3.49% versus 4.18% of patients over a mean trial follow-up of 5.8 years; odds ratio [OR], 0.94 [95% CI, 0.88-1.00]; absolute risk reduction, 0.2% [95% CI, -0.4% to 0.009%]; I2 = 0.0%). Antiplatelet therapy was not significantly associated with mean change in cognitive test scores.

conclusionIn this meta-analysis, antiplatelet therapy was not significantly associated with a lower risk of incident cognitive impairment or dementia, but the CIs around this outcome do not exclude a modest preventative effect.

Indexed as

Cognitive DysfunctionDementiaPlatelet Aggregation InhibitorsAgedHumansRandomized Controlled Trials as TopicPlatelet Aggregation InhibitorsAntiplatelet therapyCognitive impairmentDementiaDementia preventionOlder peopleSystematic Review

Identifiers

PMID37897809
PMCPMC10612993
OpenAlexW4388035025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.